#NeoGenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: https://lnkd.in/gNxygjTB #OvarianCancer #CancerTesting #Oncology
NeoGenomics Laboratories
Hospitals and Health Care
Fort Myers, Florida 32,518 followers
One Lab. Vital Answers.
Über uns
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
- Website
-
http://neogenomics.com
External link for NeoGenomics Laboratories
- Industrie
- Hospitals and Health Care
- Größe des Unternehmens
- 1.001-5.000 Mitarbeiter
- Hauptsitz
- Fort Myers, Florida
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2002
- Spezialitäten
- Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
Standorte
-
Primäre
9490 NeoGenomics Way
Fort Myers, Florida 33912, US
Employees at NeoGenomics Laboratories
Aktualisierungen
-
This article discusses how the Neo Comprehensive™–Solid Tumor Assay enhances genomic profiling to better detect actionable biomarkers, increasing the chances of targeted therapy for patients: https://lnkd.in/gu9En-em 𝐖𝐡𝐞𝐧 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬, 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 𝐰𝐡𝐨 𝐲𝐨𝐮 𝐚𝐬𝐤.
-
-
On Women's Equality Day, we celebrate the progress made towards gender equality and reaffirm our commitment to creating a more inclusive workplace. We believe that empowering women is essential to driving innovation and success, and we're proud to continue our efforts in building a more equitable future for all. #WomensEqualityDay #DiversityAndInclusion #EmpowerWomen
-
In collaboration with our Women&Allies@Neo Employee Resource Group, we were proud to host the Dress for Success SW Florida "Women Empowered Through Employment" Series at our #NeoGenomics headquarters in Fort Myers, Florida. Congratulations to this graduating cohort! To learn more about the SWFL Dress for Success program, please visit: https://lnkd.in/du9sXx-s Dress for Success Worldwide #DressForSuccess #DressForSuccessSWFL
-
-
A drug called Enhertu has been approved for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic therapy and have no satisfactory alternative treatment options. Enhertu was found to show clinically meaningful responses across a broad range of tumors, making it the first tumor-agnostic HER2-directed therapy. 𝐖𝐡𝐞𝐧 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬, 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 𝐰𝐡𝐨 𝐲𝐨𝐮 𝐚𝐬𝐤. Information about NeoGenomics’ HER2 testing can be found here: https://lnkd.in/gQfvA47W . . . ENHERTU is FDA-approved for the treatment of several types of cancer. Learn more: https://www.enhertu.com/
-
Speak with the experts in precision oncology during ESMO Congress 2024. Let’s meet during #ESMO24 to discuss how our testing capabilities, in-house expertise, and project support team can support you from discovery to commercialization.
-
-
On this Senior Citizens Day – let’s prioritize health. Regular check-ups and screenings are crucial parts of detecting cancer early. #SeniorCitizensDay #SeniorCitizensDay24 #CancerTesting #EarlyDetection Source: https://lnkd.in/gz9tjBzs
-
The AVAHO Annual Meeting runs September 20-22 in Atlanta, GA. We are proud to support AVAHO’s goal to increase the skills and abilities of veteran-centered cancer care professionals so they can provide the best possible care for our veterans. #AVAHOAnnualMeeting
-
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 200.0M